Rethinking (drug) design
The RETHINK initiative of ETH Zurich brings together experts from industry and academia to exploit the potential of artificial intelligence for design processes. ETH Prof. Gisbert Schneider and Dr. Matthias Zentgraf (Boehringer Ingelheim Pharma) explain the benefits for drug design.
Contact / Links:
Prof. Gisbert Schneider, RETHINK
Do you want to get more "News for Industry" stories?
external page Follow us on LinkedIn
Are you looking for research partners at ETH Zurich?
Contact ETH Industry Relations